抗磷脂综合征中的重度血小板减少:432例患者的回顾性研究
该单中心回顾性研究纳入432例抗磷脂综合征(APS)患者,按血小板最低值分为重度(<50 G/L)、中度(50–130 G/L)和无血小板减少(≥130 G/L)三组。随访中32.9%出现血小板减少,其中重度占13%;血小板减少组血栓事件、灾难性APS(CAPS)及多系统表现更常见,重度组总体生存更差。
要点
- APS患者随访中32.9%发生血小板减少,重度(<50 G/L)占13%。
- 血小板减少与下肢深静脉血栓、冠状动脉血栓及CAPS风险升高相关。
- 重度血小板减少治疗参照原发免疫性血小板减少症(ITP),出血时仍多维持抗凝。
核心结论
- 血小板减少与更严重的APS表型及死亡率增加相关。
研究设计与样本
- 单中心回顾性研究,纳入432例APS患者,按血小板最低值分重度(<50 G/L)、中度(50–130 G/L)和无血小板减少(≥130 G/L)三组。
主要发现
- 142例(32.9%)随访期间出现血小板减少,其中57例(13%)为重度、85例(19.4%)为中度。
- 血小板减少组下肢深静脉血栓(49% vs 37%,p=0.014)、冠状动脉血栓(15% vs 6.6%,p=0.006)和CAPS(27% vs 2.1%,p<0.001)更常见。
- 血小板减少组子痫前期(16.8% vs 3.7%,p<0.001)、皮肤溃疡(4.9% vs 1.4%,p=0.046)、皮肤坏死(7% vs 0.7%,p<0.001)、MINOCA(7% vs 0.7%,p<0.001)、瓣膜病(19.7% vs 9.3%,p=0.002)、肾脏表现(18.3% vs 3.1%,p<0.001)和肺部表现(5.6% vs 1%,p=0.007)更常见。
- 重度血小板减少病因主要为免疫性血小板减少症(ITP)和CAPS,重度组总体生存更差(p<0.0001)。
关键数值与推荐
- 重度血小板减少定义为血小板最低值<50 G/L,中度定义为50–130 G/L,无血小板减少定义为≥130 G/L。
临床怎么用
- 重度血小板减少治疗参照原发ITP方案,即使存在出血事件也通常维持抗凝。
局限性
- 单中心回顾性设计,结果需外推时谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antiphospholipid syndrome (APS) is an autoimmune disease characterised by obstetric morbidity and recurrent venous and/or arterial thrombosis. It is frequently associated with systemic lupus erythematosus, and thrombocytopenia is a common manifestation. This study aimed to compare patients with APS, with and without thrombocytopenia, and to describe management and outcomes of severe thrombocytopenia. METHODS: We performed a retrospective single-centre study that included 432 patients with APS. Patients were divided into three groups according to the platelet count nadir: severe thrombocytopenia (< 50 G/L), moderate thrombocytopenia (between 50 and 130 G/L) and no thrombocytopenia (≥ 130 G/L). RESULTS: 142 patients developed thrombocytopenia during follow-up (32.9%): 57 (13%) had severe thrombocytopenia (< 50 G/L) and 85 (19.4%) had moderate thrombocytopenia (50-130 G/L). Patients with thrombocytopenia more frequently experienced thrombotic manifestations, including lower limb deep vein thrombosis (49% vs 37%, p=0.014), coronary thrombosis (15% vs 6.6%, p=0.006) and catastrophic antiphospholipid syndrome (CAPS) (27% vs 2.1%, p<0.001). Thrombocytopenia was more frequently associated with pre-eclampsia (16.8% vs 3.7%, p<0.001) and other APS manifestations, including skin (ulcer 4.9% vs 1.4%, p=0.046, cutaneous necrosis 7% vs 0.7%, p<0.001), cardiovascular (MINOCA 7% vs 0.7%, p<0.001, valvular disease 19.7% vs 9.3%, p=0.002), renal (18.3% vs 3.1%, p<0.001) and pulmonary (5.6% vs 1%, p=0.007) manifestations. Aetiologies of severe thrombocytopenia were mainly immune thrombocytopenia (ITP) and CAPS. In patients with severe thrombocytopenia, treatment followed the approach used for primary ITP, and anticoagulation was generally maintained even in the presence of bleeding episodes. Overall survival was poorer in patients with severe thrombocytopenia (p<0.0001). CONCLUSION: Our results suggest that thrombocytopenia is associated with a more severe APS phenotype and increased mortality.
引用
- Schmidt C, Papo M, Taïeb D, et al. Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients. RMD Open. 2026. PMID: 41956709. doi:10.1136/rmdopen-2025-006504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。